The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?-Reference-Cited by-同舟云学术

The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?

Published:2024-08-18 Issue: Volume: Page:
ISSN:2192-2640
Container-title:Advanced Healthcare Materials
language:en
Short-container-title:Adv Healthcare Materials

Author:

Bannigan Pauric¹,Hickman Riley J.¹,Aspuru‐Guzik Alán¹²³⁴,Allen Christine¹²³⁵^ORCID

Affiliation:

1. Intrepid Labs Inc. MaRS Centre West Tower 661 University Avenue Suite 1300 Toronto ON M5G 0B7 Canada

2. Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto ON M5S 3E5 Canada

3. Acceleration Consortium University of Toronto Toronto ON M5S 3H6 Canada

4. Department of Chemistry University of Toronto Toronto ON M5S 3H6 Canada

5. Leslie Dan Faculty of Pharmacy University of Toronto Toronto ON M5S 3M2 Canada

Abstract

AbstractOver the last four decades, pharmaceutical companies’ expenditures on research and development have increased 51‐fold. During this same time, clinical success rates for new drugs have remained unchanged at about 10 percent, predominantly due to lack of efficacy and/or safety concerns. This persistent problem underscores the need to innovate across the entire drug development process, particularly in drug formulation, which is often deprioritized and under‐resourced.

Funder

Natural Sciences and Engineering Research Council of Canada

Canada First Research Excellence Fund

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adhm.202401312

Reference101 articles.

1. Why 90% of clinical drug development fails and how to improve it?

2. Research and Development in the Pharmaceutical Industry | Congressional Budget Office https://www.cbo.gov/publication/57025 2021.

3. PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021 https://phrma.org/Blog/phrma‐member‐companies‐rd‐investments‐reach‐record‐high‐of‐1023‐billion‐in‐2021 2021.

4. Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach